Jonathan Davies

Mr. Jonathan Davies


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in Science
Verified
Journal Article
Closed access
MMMaurice Michel
Maurice Michel
CBCarlos Benítez-Buelga
Carlos Benítez-Buelga
PCPatricia A. Calvo
Patricia A. Calvo
BHBishoy M. F. Hanna
Bishoy M. F. Hanna
OMOliver Mortusewicz
Oliver Mortusewicz
THThomas Helleday
Thomas Helleday
Oxidative DNA damage is recognized by 8-oxoguanine (8-oxoG) DNA glycosylase 1 (OGG1), which excises 8-oxoG, leaving a substrate for apurinic endonuclease 1 (APE1) and initiating repair. Here, we describe a small molecule (TH10785) that interacts with the phenylalanine-319 and glycine-42 amino acids of OGG1, increases the enzyme activity 10-fold, and generates a previously undescribed β,δ-lyase enzymatic function. TH10785 controls the catalytic activity mediated by a nitrogen base within its molecular structure. In cells, TH10785 increases OGG1 recruitment to and repair of oxidative DNA damage. This alters the repair process, which no longer requires APE1 but instead is dependent on polynucleotide kinase phosphatase (PNKP1) activity. The increased repair of oxidative DNA lesions with a small molecule may have therapeutic applications in various diseases and aging.

20 October 2018 in Toxins
Verified
Journal Article
Open access
PDF file
JDJonathan Davies
Jonathan Davies
SLSai Liu
Sai Liu
KAK. Ravi Acharya
K. Ravi Acharya
Botulinum neurotoxins (BoNTs) are categorised into immunologically distinct serotypes BoNT/A to /G). Each serotype can also be further divided into subtypes based on differences in amino acid sequence. BoNTs are ~150 kDa proteins comprised of three major functional domains: an N-terminal zinc metalloprotease light chain (LC), a translocation domain (HN), and a binding domain (HC). The HC is responsible for targeting the BoNT to the neuronal cell membrane, and each serotype has evolved to bind via different mechanisms to different target receptors. Most structural characterisations to date have focussed on the first identified subtype within each serotype (e.g., BoNT/A1). Subtype differences within BoNT serotypes can affect intoxication, displaying different botulism symptoms in vivo, and less emphasis has been placed on investigating these variants. This review outlines the receptors for each BoNT serotype and describes the basis for the highly specific targeting of neuronal cell membranes. Understanding receptor binding is of vital importance, not only for the generation of novel therapeutics but also for understanding how best to protect from intoxication.

1 September 2015 in Scientific Reports
Verified
Journal Article
Open access
GMGeoffrey Masuyer
Geoffrey Masuyer
JDJonathan Davies
Jonathan Davies
KMKevin Moore
Kevin Moore
JCJohn A. Chaddock
John A. Chaddock
KAK. Ravi Acharya
K. Ravi Acharya
The botulinum neurotoxin type D is one of seven highly potent toxins produced byClostridium botulinumwhich inhibit neurotransmission at cholinergic nerve terminals. A functional fragment derived from the toxin, LHn, consisting of the catalytic and translocation domains, has been heralded as a platform for the development of targeted secretion inhibitors. These secretion inhibitors are aimed at retargeting the toxin towards a specific cell type to inhibit vesicular secretion. Here we report crystal structures of LHn from serotype D at 2.3?Å and that of SXN101959 at 3.1?Å resolution. SXN101959, a derivative that combines LHn from serotype D with a fragment of the growth hormone releasing hormone, has previously revealed promising results in inhibiting growth hormone release in pituitary somatotrophs. These structures offer for the first time insights into the translocation domain interaction with the catalytic domain in serotype D. Furthermore, structural information from small-angle X-ray scattering of LHn/D is compared among serotypes A, B and D. Taken together, these results demonstrate the robustness of the ‘LHn fold’ across serotypes and its use in engineering additional polypeptide components with added functionality. Our study demonstrates the suitability of botulinum neurotoxin and serotype D in particular, as a basis for engineering novel secretion inhibitors.

1 May 2018 in Journal of Structural Biology
Verified
Journal Article
Closed access
JDJonathan Davies
Jonathan Davies
JRJay Rees
Jay Rees
SLSai Liu
Sai Liu
KAK. Ravi Acharya
K. Ravi Acharya

21 March 2018 in PeerJ
Verified
Journal Article
Open access
PDF file
JDJonathan Davies
Jonathan Davies
GHGavin S. Hackett
Gavin S. Hackett
SLSai Liu
Sai Liu
KAK. Ravi Acharya
K. Ravi Acharya
The binding specificity of botulinum neurotoxins (BoNTs) is primarily a consequence of their ability to bind to multiple receptors at the same time. BoNTs consist of three distinct domains, a metalloprotease light chain (LC), a translocation domain (HN) and a receptor-binding domain (HC). Here we report the crystal structure of HC/FA, complementing an existing structure through the modelling of a previously unresolved loop which is important for receptor-binding. Our HC/FA structure also contains a previously unidentified disulphide bond, which we have also observed in one of two crystal forms of HC/A1. This may have implications for receptor-binding and future recombinant toxin production.

Verified
Journal Article
Open access
PDF file
GMGeoffrey Masuyer
Geoffrey Masuyer
JDJonathan Davies
Jonathan Davies
PSPål Stenmark
Pål Stenmark
The botulinum neurotoxins are potent molecules that are not only responsible for the lethal paralytic disease botulism, but have also been harnessed for therapeutic uses in the treatment of an increasing number of chronic neurological and neuromuscular disorders, in addition to cosmetic applications. The toxins act at the cholinergic nerve terminals thanks to an efficient and specific mechanism of cell recognition which is based on a dual receptor system that involves gangliosides and protein receptors. Binding to surface-anchored gangliosides is the first essential step in this process. Here, we determined the X-ray crystal structure of the binding domain of BoNT/E, a toxin of clinical interest, in complex with its GD1a oligosaccharide receptor. Beyond confirmation of the conserved ganglioside binding site, we identified key interacting residues that are unique to BoNT/E and a significant rearrangement of loop 1228–1237 upon carbohydrate binding. These observations were also supported by thermodynamic measurements of the binding reaction and assessment of ganglioside selectivity by immobilised-receptor binding assays. These results provide a structural basis to understand the specificity of BoNT/E for complex gangliosides.